• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 29, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Disrupting prostate cancer ‘homing signal’ could hold promise for new treatments

Bioengineer by Bioengineer
March 20, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
Loading video…

Credit: Centre for Developmental Neurobiology, King's College London.

New King's College London research sheds light on the cellular mechanisms which enable cancer cells to escape the prostate and spread to other parts of the body.

Published today in the journal Oncogene, the findings suggest that it may one day be possible to therapeutically disrupt the 'homing signal' which causes prostate cancer cells to enter the bloodstream and form secondary tumours.

Prostate cancer is the most common cancer in men, with 40,000 new cases a year in the UK. Advanced 'metastatic' prostate cancer develops when cancer cells spread through the blood stream or lymphatic system, where they establish secondary tumours on lymph nodes or bone.

The metastatic form of the disease is currently incurable and despite advances in diagnosis, 30 per cent of men diagnosed with prostate cancer already have metastatic cancer by the time they present at the clinic.

Clinicians are currently unable to predict which prostate tumours will become metastatic and establish secondary tumours in other tissues, and which ones will remain within the prostate. Identifying a molecular pathway that contributes to this process could guide treatment by helping clinicians distinguish between the two forms of cancer, and it could also assist with singling out targets for therapeutic intervention.

A team of scientists and clinicians from King's College London's Institute of Psychiatry, Psychology & Neuroscience (IoPPN) and the University of Oxford examined the cellular machinery of benign and malignant human prostate tissue and human prostate cancer cell lines.

They discovered a molecular pathway that organises the cytoskeleton (a skeletal frame which gives shape to a cell) and enables cells to respond to homing signals and invade other tissue outside the prostate. At the core of this pathway are two proteins called drebrin and EB3, which control the movement of cells through the outer layer of the prostate and into the bloodstream or lymphatic system (a system of thin tubes and lymph nodes that run throughout the body and are an important part of the immune system).

Senior author of the study, Professor Phillip Gordon-Weeks from the Centre for Developmental Neurobiology at the IoPPN, King's College London, said: 'Prostate cancer cells are attracted to the tissue they invade by homing signals released from these tissues. We've now identified the cellular machinery that guides this process and we think these homing signals could one day be disrupted therapeutically to stop cancer cells escaping the primary tumour and invading the body to form secondary tumours.

'This research provides a really compelling example of how basic research can drive and inform translational research. Using animal models, we now need to examine how the prostate cancer homing signal could be manipulated using treatments.'

###

This work was principally supported by a grant from the King's Health Partners Research and Development Challenge Fund.

Media Contact

Jack Stonebridge
[email protected]
020-784-85377
@kingscollegelon

http://www.kcl.ac.uk

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Isolating a Robust Heat-Resistant Metalloprotease from Geobacillus

Isolating a Robust Heat-Resistant Metalloprotease from Geobacillus

August 29, 2025

NEXN Prevents Vascular Calcification via SERCA2 SUMOylation

August 29, 2025

Predictive Models Shape Transplant Eligibility Decisions

August 29, 2025

Enhanced Visualization of Microcystic Macular Edema in OCT

August 29, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    151 shares
    Share 60 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    82 shares
    Share 33 Tweet 21

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Isolating a Robust Heat-Resistant Metalloprotease from Geobacillus

NEXN Prevents Vascular Calcification via SERCA2 SUMOylation

Predictive Models Shape Transplant Eligibility Decisions

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.